Oral sodium phosphate laxative inducing hyperphosphatemia relates with weight?
- Date:
- January 15, 2010
- Source:
- World Journal of Gastroenterology
- Summary:
- A research team from Argentina prospectively studied the frequency of hyperphosphatemia following the administration of oral sodium phosphate (OSP) in low-risk patients. They found that the standard dose of OSP-laxative-induced hyperphosphatemia is related to body weight.
- Share:
Colon cleansing is used widely for colonoscopic exploration and colonic and gynecological surgery. Oral sodium phosphate (OSP) solution is the osmotic laxative most commonly used for this purpose. It is known that OSP can induce severe hyperphosphatemia and hypocalcemia due to excessive absorption of phosphates, and there have been reports of deaths and irreversible dialysis-requiring renal insufficiency. However, no prospective studies have investigated the prevalence of hyperphosphatemia in low-risk patients.
A research article to be published on December 21, 2009 in the World Journal of Gastroenterology addresses this question. A research team from Argentina recruited one hundred consecutive ASA Ⅰ-Ⅱ individuals aged 35-74 years to study the frequency of hyperphosphatemia following the administration of OSP.
They found that in low-risk, well-hydrated patients, hyperphosphatemia following standard OSP doses is related to weight.
Their results suggest performing preoperative evaluation aimed at avoiding administration of OSP laxatives to patients at risk; reducing the dose of OSP in patients with low weight; and avoiding dehydration with an adequate oral intake of clear liquids.
Story Source:
Materials provided by World Journal of Gastroenterology. Note: Content may be edited for style and length.
Journal Reference:
- Casais MN, Rosa-Diez G, Pérez S, Mansilla EN, Bravo S, Bonofiglio FC. Hyperphosphatemia after sodium phosphate laxatives in low risk patients: Prospective study. World Journal of Gastroenterology, 2009; 15 (47): 5960 DOI: 10.3748/wjg.15.5960
Cite This Page: